(Q36360811)

13 August 2017

1 reference

title

Metabolism and transport of oxazaphosphorines and the clinical implications (English)

1 reference

13 August 2017

Jing Zhang

1

1 reference

13 August 2017

Quan Tian

2

1 reference

13 August 2017

Sui Yung Chan

3

1 reference

13 August 2017

Shu Chuen Li

4

1 reference

13 August 2017

Shufeng Zhou

5

1 reference

13 August 2017

Wei Duan

6

1 reference

13 August 2017

Yi-Zhun Zhu

7

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

13 August 2017

Drug Metabolism Reviews

1 reference

13 August 2017

37

1 reference

13 August 2017

611-703

1 reference

13 August 2017

4

1 reference

IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation

13 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacogenetics of alcohol metabolism and alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Renal ontogeny of ifosfamide nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A tubule cell model for ifosfamide nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetics of ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Trofosfamide as salvage therapy for anaplastic large cell lymphoma relapsing after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

MICE: a new active combination for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosamide, epirubicin and granulocyte colony-stimulating factor: a regimen for successful mobilization of peripheral blood progenitor cells in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The prognosis of lupus nephritis in African-Americans: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetic drug interactions of commonly used anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug beta-D-glucosyl-ifosfamide mustard

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Intrathecal mafosfamide: a preclinical pharmacology and phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Metabolism and pharmacokinetics of oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Mammalian ABC transporters in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The multidrug resistance protein family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosfamide--pharmacology, safety and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Basis and new developments in the field of oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

High-dose cyclophosphamide for aplastic anemia and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Role of Ifosfamide in Cervical Cancer: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA i

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Dependence of aldehyde dehydrogenase-mediated oxazaphosphorine resistance on soluble thiols: importance of thiol interactions with the secondary metabolite acrolein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cyclophosphamide potentiation and aldehyde oxidase inhibition by phosphorylated aldehydes and acetals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Bioavailability of ifosfamide in patients with bronchial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The effects of nitrogen mustards on the proliferative and Ig synthetic response of human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Chemotherapy of small cell lung cancer: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Dose density in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosfamide-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

From bench to bedside for gene-directed enzyme prodrug therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Evaluating risk factors for the development of ifosfamide encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Aldehyde dehydrogenase involvement in a variant of the brown Norway rat acute myelocytic leukaemia (BNML) that acquired cyclophosphamide resistance in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Oral chemotherapy: rationale and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Tumor-activated prodrugs--a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Hallucinations and ifosfamide-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetics of Cyclophosphamide after prolonged low dose treatment in ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Hematopoietic stem cells and other hematopoietic cells show broad resistance to chemotherapeutic agents in vivo when overexpressing bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Human red blood cells: rheological aspects, uptake, and release of cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacogenetics: the therapeutic drug monitoring of the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacological therapy of lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Alkylating agent resistance: in vitro studies with human cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Long-term results of dose density therapy in patients with aggressive lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification of the novel splicing variants for the hPXR in human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacology of Ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The initial clinical trial of nitrogen mustard

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Systemic lupus erythematosus trials: successes and issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Biochemistry of multidrug resistance mediated by the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The macrophage - a novel system to deliver gene therapy to pathological hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Current clinical practices for ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Metabolism of ifosfamide during a 3 day infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

21 January 2018

Glutathione transferases

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Erythrocytes and the transport of drugs and endogenous compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Human aldehyde dehydrogenase genes, ALDH7 and ALDH8: genomic organization and gene structure comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The systemic treatment of advanced and metastatic bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Functional characterization of cytochrome P450 2B6 allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetics of cyclophosphamide in Kenyan Africans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cytochrome P450-based cancer gene therapy: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The molecular effects of acrolein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Side Effects of Ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

MRP3, an organic anion transporter able to transport anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The effects of impaired liver function on the elimination of antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Trofosfamide in the palliative treatment of cancer: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Therapeutic drug monitoring of antimetabolic cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Mutation analysis of the multidrug resistance protein 2 (MRP2) gene in a Japanese patient with Dubin-Johnson syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Nitrogen mustard inhibits transcription and translation in a cell free system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

GST-pi gene-transduced hematopoietic progenitor cell transplantation overcomes the bone marrow toxicity of cyclophosphamide in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Therapeutic drug monitoring opportunities in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Expression of glucose transporter-1 in cervical cancer and its precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetics of divided‐dose ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A proof of glutathione S-transferase-pi-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Characterization of the catecholamine extraneuronal uptake2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Tumour cytochrome P450 and drug activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

TAC--a new standard in adjuvant therapy for breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cyclophosphamide: new approaches for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacogenomics in cancer therapy: is host genome variability important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the Nationa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Novel competitive irreversible inhibitors of aldehyde dehydrogenase (ALDH1): restoration of chemosensitivity of L1210 cells overexpressing ALDH1 and induction of apoptosis in BAF(3) cells overexpressing bcl(2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Structure and expression of the cytosolic aldehyde dehydrogenase gene in cyclophosphamide-resistant murine leukemia L1210 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Acrolein mercapturates: synthesis, characterization, and assessment of their role in the bladder toxicity of cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by chlorpropamide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cancer chemotherapy and drug metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The molecular basis of Sjögren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetic interactions with digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Enzyme-catalyzed activation of anticancer prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Detailed genetic and physical mapping in the Sjögren-Larsson syndrome gene region in 17p11.2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cardiotoxicity of cancer chemotherapy: implications for children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosfamide, mesna, and nephrotoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Metabolism of oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Aldehyde dehydrogenase gene superfamily: the 2000 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Aldehyde dehydrogenase gene superfamily: the 2002 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosfamide in Advanced/Disseminated Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Isophosphoramide Mustard and Its Mechanism of Bisalkylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Phenolic antioxidant-induced overexpression of class-3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification of the class-3 aldehyde dehydrogenases present in human MCF-7/0 breast adenocarcinoma cells and normal human breast tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Efficacy of two different platinum- or anthracycline-containing chemotherapy regimens for the treatment of small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Theory, targets and therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Ifosfamide clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification of a novel 2026G-->C mutation of the MRP2 gene in a Japanese patient with Dubin-Johnson syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

A mouse-based strategy for cyclophosphamide pharmacogenomic discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Enantioselective induction of cyclophosphamide metabolism by phenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

PXR, CAR and drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cytogenetic mechanisms in the selective toxicity of cyclophosphamide analogs and metabolites towards avian embryonic B lymphocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Molecular genetics of human aldehyde dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Human aldehyde dehydrogenase gene family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Lymphoma: diagnosis, staging, natural history, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Noninvasive tests of CYP3A enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Genetic predisposition to drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03602530500364023

10.1080/03602530500364023

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference